Department of Endocrinology and Diabetes, Xiamen Diabetes Institute, and Xiamen Clinical Medical Center for Endocrine and Metabolic Diseases, the First Affiliated Hospital of Xiamen University, Xiamen, China; Fujian Province Key Laboratory of Diabetes Translational Medicine, Xiamen, China.
Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA; Tulane University Translational Science Institute, New Orleans, LA.
Am Heart J. 2021 Aug;238:45-58. doi: 10.1016/j.ahj.2021.04.009. Epub 2021 May 4.
Diabetes has become a major public health challenge worldwide, especially in low- and middle-income countries (LMICs). Uncontrolled hyperglycemia, hypertension, and dyslipidemia major risk factors for all-cause mortality and cardiovascular disease (CVD) are common in patients with diabetes in China. We propose to compare the effectiveness of team-based care plus a clinical decision support system (CDSS) with team-based care alone on glycemic, blood pressure (BP), and lipid control, and clinical CVD reduction among patients with type-2 diabetes and at high risk for CVD.
The Diabetes Complication Control in Community Clinics (D4C) study is a cluster-randomized trial conducted among 38 community health centers in Xiamen City, China. Nineteen clinics have been randomly assigned to team-based care plus CDSS and 19 to team-based care alone. Team-based care includes primary care providers, health coaches, and diabetes specialists working collaboratively with patients to achieve shared treatment goals for CVD risk factor reduction. The CDSS integrates guideline-based treatment algorithms for glycemic, BP, and lipid control, along with a patient's medical history and insurance policy, to recommend treatment and follow-up plans. In phase 1, the co-primary outcomes are mean reduction in glycated hemoglobin (HbA1c), systolic BP (SBP), and low-density lipoprotein (LDL)-cholesterol over 18 months, and the proportion of patients with controlled HbA1c, SBP, and LDL-cholesterol at 18 months' between the 2 comparison groups. In phase 2, the primary outcome is the difference in major CVD incidence (non-fatal stroke, non-fatal myocardial infarction, hospitalized heart failure, and CVD mortality) between the 2 comparison groups. Mean reduction in HbA1c, SBP, and LDL-cholesterol levels will be simultaneously modeled for a single overall treatment effect.
The D4C trial will generate evidence on whether a CDSS will further reduce the CVD burden among patients with diabetes beyond team-based care at community clinics. If proven effective, this implementation strategy could be scaled up within primary care settings in China and other LMICs to reduce CVD incidence and mortality among patients with diabetes.
糖尿病已成为全球主要的公共卫生挑战,尤其是在中低收入国家(LMICs)。在中国的糖尿病患者中,血糖控制不佳、高血压和血脂异常是全因死亡率和心血管疾病(CVD)的主要危险因素。我们提出将团队护理加临床决策支持系统(CDSS)与单独的团队护理进行比较,以评估其在控制 2 型糖尿病和高 CVD 风险患者的血糖、血压(BP)和血脂方面的有效性,并降低临床 CVD 事件。
社区诊所中的糖尿病并发症控制(D4C)研究是在中国厦门市的 38 个社区卫生中心进行的一项集群随机试验。19 个诊所被随机分配到团队护理加 CDSS 组和团队护理组。团队护理包括初级保健提供者、健康教练和糖尿病专家,他们与患者合作,共同实现 CVD 危险因素降低的共同治疗目标。CDSS 整合了基于指南的血糖、BP 和血脂控制治疗算法,以及患者的病史和保险政策,以推荐治疗和随访计划。在第 1 阶段,共同主要结局是在 18 个月内糖化血红蛋白(HbA1c)、收缩压(SBP)和低密度脂蛋白(LDL)-胆固醇的平均降低,以及在 18 个月时,2 个比较组中 HbA1c、SBP 和 LDL-胆固醇得到控制的患者比例。在第 2 阶段,主要结局是 2 个比较组之间主要 CVD 发病率(非致命性中风、非致命性心肌梗死、住院心力衰竭和 CVD 死亡率)的差异。HbA1c、SBP 和 LDL-胆固醇水平的平均降低将同时建模为单一的总体治疗效果。
D4C 试验将提供有关 CDSS 是否会在社区诊所的团队护理之外进一步降低糖尿病患者 CVD 负担的证据。如果被证明有效,这种实施策略可以在中国和其他 LMICs 的基层医疗环境中扩大规模,以降低糖尿病患者的 CVD 发病率和死亡率。